Forging ahead with its new three-year business plan, Chugai Pharmaceutical enjoyed rosy earnings in the first half of 2019, bolstered by the outperformance of the Hemlibra (emicizumab) hemophilia drug and its I/O star Tecentriq (atezolizumab). But with a biosimilar onslaught…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Biogen/Eisai’s Aducanumab Fails, Dashing Hopes in Alzheimer’s Field
March 22, 2019
-
BUSINESS Gilead Set to Duplicate Biktarvy Success in Japan with New Stand-Alone HIV Sales Force
March 20, 2019
-
BUSINESS Employee Sues Bayer Japan for Emotional Distress over Xarelto Scandal
March 19, 2019
-
ORGANIZATION Kenporen Director Kono: Apply CEA to Reimbursement Decisions Once Credible System Established
March 18, 2019
-
BUSINESS Drug Makers, Wholesalers Establishing Supervisory Divisions as Detailing Guidelines Rollout Nears
March 15, 2019
-
REGULATORY MHLW to Promote Master Protocol Trials to Boost Efficiency in New Drug Development
March 14, 2019
-
BUSINESS Fujifilm Going Full Throttle in CDMO Biz with Buyout of Biogen Unit
March 13, 2019
-
REGULATORY Detailing Guidelines Casting Clouds over Drug Maker-Sponsored Press Seminars?
March 12, 2019
-
BUSINESS Meiji Pharma Pursuing Low-Cost Strategy to Weather Storm in Generics Space, Overseas Plants Hold Key
March 11, 2019
-
BUSINESS Eisai CEO Says “20% ROE in 2025” within Reach If All 3 Alzheimer’s Candidates, Lenvima Deliver
March 8, 2019
-
INTERVIEW JMA Exec Matsumoto: CEA Scheme Merely a Supplemental Tool to Drug Pricing System, Continued Discussions Necessary
March 7, 2019
-
BUSINESS Pfizer Japan Logs 2.6% Growth in FY2018, No Job Cut Planned: Chief
March 6, 2019
-
TRENDS Drug Makers on Hunt for “Mibyo” Biz Opportunities as Pricing Rules Get Stricter
March 5, 2019
-
COMMENTARY Generic Makers Shifting to Focus on “Specialty Area” Faced with Tougher Business Environment
March 4, 2019
-
BUSINESS More Pharmacies Turning to Medical System Network’s Price Negotiation Service after Distribution Guidelines Introduced
March 1, 2019
-
REGULATORY MHLW to Impose Administrative Fines Only on Misleading Ads, Eyes 4.5% Charge: PMD Law
February 28, 2019
-
ACADEMIA Investigators Calling Off Trials on First Hyperlactacidemia Drug with No Significant Improvement Shown
February 28, 2019
-
BUSINESS Nihon Generic Taking Pass on June Listing of Symbicort Copies; 2 Partners Mum
February 27, 2019
-
BUSINESS Shionogi Specialty Squad Providing Deep Info on Mulpleta/Pirespa, Aims for Higher Sales with Fewer Calls
February 26, 2019
-
BUSINESS Takeda Japan Chief Says Shire Buy Only Bolsters Home Operations with No Overlaps, Nixes Job Cuts
February 25, 2019
ページ
Generic drug makers are making greater efforts to disclose more information on their products after years of repeated requests from doctors and medical institutions, which want to better ascertain their quality and stability of their supplies.Ohara Pharmaceutical has been disclosing…
Riding on the back of an improved regulatory environment in China, major Japanese drug makers are moving to expand their businesses in the world’s second largest pharma market. Companies are pumping up their new drug pipelines, while forging solid sales…
As Japan heralds the new imperial era of Reiwa, Eisai CEO Haruo Naito sat with Jiho to look back on…
Japan’s generic market is hitting a plateau soon. Incentive measures rolled out by the government since 2002 have driven its…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
In 2011 the Japanese pharmaceutical industry was rocked when a whistleblower exposed the falsification of trial data for the drug Diovan, the blockbuster blood pressure drug manufactured by pharma giant Novartis. The ensuing investigation led to the arrest of one…